Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716803 | 1.00 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL321431 | 1.00 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL10192702 | 1.00 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| Hydrochloric Acid SCHEMBL595131 | 0.98 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2ADPP4 | |
| Hydrochloric Acid SCHEMBL2083204 | 0.98 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL10633429 | 0.91 | ALOX15 (0.47) | ALOX15BLMPMP22KMT2ADPP4 | |
| Glutamic Acid SCHEMBL19128265 | 0.88 | ALOX15 (0.63) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL11776470 | 0.84 | SMN1; SMN2 (0.42) | LTA4HSLC1A1CA1CA2SMN1; SMN2 | |
| SCHEMBL12601005 | 0.83 | LTA4H (0.40) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL18870212 | 0.83 | ALOX15 (0.52) | ALOX15BLMPMP22KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115559-A1 | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections | SEN JAM PHARMACEUTICAL INC (US) | 2024-04-11 | — | — | US | disclosed |
| US-11911355-B2 | Methods and compositions to inhibit tolerance to opioids | SEN-JAM PHARMACEUTICAL INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11883388-B2 | Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections | SEN-JAM PHARMACEUTICAL INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11793800-B2 | Methods and compositions to inhibit adverse effects associated with vaccinations | SEN-JAM PHARMACEUTICAL INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11597724-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxylic acids and esters | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-07 | — | — | US | disclosed |
| US-20230064685-A1 | METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VEISALGIA | SEN JAM PHARMACEUTICAL LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220265585-A1 | Methods and Compositions to Inhibit Symptoms Associated with Opioid Withdrawal | SEN-JAM PHARMACEUTICAL INC. | 2022-08-25 | — | — | US | disclosed |
| EP-3273952-B1 | COMBINATION OF NAPROXEN AND FEXOFENADINE TO INHIBIT SYMPTOMS ASSOCIATED WITH VEISALGIA | SEN JAM PHARMACEUTICAL LLC (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11129803-B2 | Methods and compositions to inhibit tolerance to opioids | SEN-JAM Pharmaceutical LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210212971-A1 | Methods and Compositions to Inhibit Dependence on Opioids | SEN-JAM PHARMACEUTICAL INC. | 2021-07-15 | — | — | US | disclosed |
| CN-101080400-A | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| EP-1797068-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES | CELGENE CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006028964-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES | CELGENE CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052609-A1 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1572065-A2 | METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Rappaport Family Institute for Research in the Medical Sciences (IL) | 2005-09-14 | — | — | EP | disclosed |
| WO-2002098346-A2 | METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2002-12-12 | — | — | WO | disclosed |
| EP-1117681-A4 | NOVEL PEPTIDES | UNIV QUEENSLAND (AU) | 2002-01-02 | — | — | EP | disclosed |
| EP-1117681-A1 | NOVEL PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020443-A1 | NOVEL PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2000-04-13 | — | — | WO | disclosed |
| WO-1997035573-A2 | NSAIDs IN THE TREATMENT OF PRURITUS | THE BOOTS COMPANY PLC (GB) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883388-B2 | Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections | CMA1, NISCH, HRH2 | ALOX15 237/4885BLM 4543/4885PMP22 2953/4885 |
| US-11597724-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxylic acids and esters | AADAC, DDT, DPP7 | ALOX15 1900/4885BLM 4555/4885PMP22 4365/4885 |
| US-20060052609-A1 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | TNF, IL1A, TRAF2 | ALOX15 482/4885BLM 4070/4885PMP22 2412/4885 |
| US-20240115559-A1 | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections | CMA1, NISCH, HRH2 | ALOX15 237/4885BLM 4543/4885PMP22 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.